Drugs / ANS014004
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06307795 | Jun 2024 → Apr 2027 expected | — | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06328439 | May 2024 → Dec 2027 expected | — | Avistone Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07285148 | Jun 2026 → Dec 2029 expected | non-small cell lung carcinoma | Beijing Pearl Biotechnology Limited Liability Company | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANS014004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06328439 ↗ |
| Action | Inhibit | “designed to block a protein called MET” NCT07285148 ↗ |
| Modality | Small molecule | “Investigational Type II MET tyrosine kinase inhibitor” NCT07285148 ↗ |
| Route | Oral | “subjects will receive oral administration of ANS014004” NCT06328439 ↗ |
| Target | MET | “Targets MET exon 14 skipping, amplification, overexpression, and fusions.” NCT07285148 ↗ |